Genetron Health Strengthens Partnership with Thermo Fisher Scientific to Expand Precision Cancer Diagnosis and Monitoring Across China�s Public Hospitals

BEIJING–(BUSINESS WIRE)–Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, has entered into a strategic partnership agreement with Thermo Fisher Scientific (“Thermo Fisher”). With plans to build on the sequencer Genetron S5 (Registration Number 20193220820), the partnership aims to enhance innovation, commercialization and promotion of next-generation sequencing (NGS) platforms in the field of molecular cancer diagnosis in China’s public hospitals.

The partnership will introduce the Company’s medium-throughput NGS system Genetron S5 to public hospitals across China, promoting the application and development of Genetron S5 in more fields, such as reproductive health, genetic disease, pathological microorganism testing, and other independent clinical lab testing and scientific research.

“Genetron Health is committed to leading and empowering the cancer diagnostics and treatment industry,” said Wang Sizhen, Co-Founder and CEO of Genetron Health. “We have been working with Thermo Fisher, one of our world-class partners, to create open, flexible, convenient and accurate molecular diagnostic products, and to offer a comprehensive one-stop solution. Our products and solutions are designed to empower medical institutions continuously improve their diagnostic and treatment capabilities, bringing more accurate and speedy services to the public.”

“ Thermo Fisher’s memorandum of understanding with Genetron in this field will help further our companies’ work together to develop IVD solutions for the fast-growing Chinese market,” said Tony Acciarito, president of Thermo Fisher Scientific China “We look forward to generating significant customer value and promoting precision medicine to improve public health throughout China.”

Genetron Health has received National Medical Products Administration (NMPA) approval for clinical application of seven IVD products, which cover three major technology platforms: the NGS, dPCR and qPCR. The NGS platform, in particular, provides flexible combinations of products with low, medium and high-throughput. Genetron Health also offers overall R&D and commercialization solutions for in vitro diagnostic technologies available on multiple technology platforms and in various application scenarios, by fully exploring and tapping into the unique strength of each technology platform.

About Genetron S5

Genetron S5 platform approved by NMPA on November 1, 2019, is a medium-throughput NGS system that enables simple targeted sequencing workflows at an affordable price, without compromising on performance or reliability. Genetron S5 platform offers several throughput options, which provide the flexibility to scale from small to large projects, enabling multiple targeted sequencing applications on a single system. Based on the design, Genetron S5 is particularly suitable for hospitals as it offers more practical solutions and greater scalability.

About Genetron Health

Genetron Health a leading and fast-growing precision oncology company in China that aims to provide one-stop genomic profiling solutions for multiple scenarios covering early screening, diagnosis and monitoring, and biopharmaceutical services. The company collaborates with over 500 hospitals and dozens of biopharmaceutical companies and research institutions, and has developed a large proprietary genomic database.

Genetron Health has established R&D centers in both the United States and China, two manufacturing facilities with both ISO 13485:2016 certification and ISO 9001 2015 certification in China and five clinical laboratories in Beijing (CLIA accreditation and CAP certification), Shanghai, Hangzhou, Chongqing and Guangzhou. The R&D capacities of Genetron Health are supported by a best-in-class research and development team led by scientists at the forefront of cancer genomics research. The company has published many research papers in highly influential worldwide peer-reviewed scientific journals, such as Nature Genetics, Nature Communications, Cell Research and PNAS. For more information, please visit www.genetronhealth.com.

Contacts

Media Contact:
Edmond Lococo

ICR

Edmond.Lococo@icrinc.com
Mobile: +86 138-1079-1408

Investor Contact:
Stephanie Carrington

Westwicke, an ICR Company

Stephanie.Carrington@westwicke.com
Office: +1 (646) 277-1282